MTHFR is one step in a much longer cycle
MTHFR is one step in a much longer cycle
MTHFR is one enzyme in the folate cycle, a sequence of reactions that converts dietary folate into the active form the body uses to recycle homocysteine, build DNA and support methylation. A common variant, C677T, lowers that enzyme's efficiency. That much is real, and it is also where most of the public conversation stops.
The cycle needs several enzymes working in order. MTHFD1 carries out three separate reactions that direct folate towards DNA synthesis. MTR, or methionine synthase, performs the step that MTHFR's product is made for, converting homocysteine back to methionine, and it cannot run without vitamin B12. MTRR keeps MTR's B12 cofactor in working condition. Common variants in each of these have been linked to folate handling and homocysteine, which is why one MTHFR result was never going to summarise the pathway.
There is also a gap between carrying a variant and having a problem. Genotype is fixed at birth. Folate and B12 status shift with diet, absorption, medication, pregnancy and age. Two people with identical MTHFR results can sit in very different places clinically, because what determines the cycle's output is the enzymes and the nutrients feeding them together.
This is why genetics bodies advise against routine MTHFR testing, and why the measurements that change management are functional rather than genetic. Homocysteine reflects how the whole cycle is running now. Active B12 and folate show whether the raw materials are present. Both can be re-checked after treatment to see whether anything moved. A gene result cannot do either.
What the folate cycle actually does
The folate cycle is a loop. Folate arrives from food or a supplement, passes through several chemical forms, and its end product hands a methyl group to homocysteine, converting it back to methionine. Methionine then becomes S-adenosylmethionine, the body's main methyl donor for hundreds of reactions, including DNA methylation, neurotransmitter production and the upkeep of myelin.[1][2]
Two things follow. Folate and B12 work as two halves of one reaction, so a shortage of either stalls it. Homocysteine sits at the junction and builds up whenever the cycle slows. It cannot tell you which step is struggling, but it does show the pathway is not keeping up.[1]
MTHFR is one enzyme of several
MTHFR converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, the form that donates the methyl group. The C677T variant produces a heat-sensitive enzyme with reduced activity, and people carrying two copies tend to run higher homocysteine, most noticeably when folate status is low.[4] A second variant, A1298C, also lowers activity, less sharply.[3]
This is worth separating from severe MTHFR deficiency, a genuine inborn error of metabolism. That condition is rare, appears in infancy with neurological disease and markedly elevated homocysteine, and has little in common with a variant on a consumer gene report.[5] Much of the alarm around MTHFR comes from the two being discussed as one.
One detail rarely survives into the online discussion. MTHFR's cofactor is riboflavin, vitamin B2, and a randomised trial found riboflavin supplementation lowered homocysteine specifically in people with the C677T genotype.[6][4] The variant's effect is shaped by the nutrients available to it, which is why a genotype alone predicts so little.
The genes that rarely get mentioned
MTHFD1 is a trifunctional enzyme, meaning a single protein performs three distinct reactions in the cycle, largely directing folate towards DNA synthesis rather than methylation. The common R653Q variant changes how the enzyme behaves and has been studied in relation to congenital heart defects and pregnancy outcomes.[7]
MTR, methionine synthase, carries out the remethylation step itself, and its cofactor is methylcobalamin, a form of vitamin B12. Variants in MTR have been examined alongside MTHFR for their combined effect on one-carbon markers.[8]
MTRR, methionine synthase reductase, regenerates that B12 cofactor once it oxidises. The A66G variant has been identified as a determinant of plasma homocysteine in its own right.[9] One study of one-carbon metabolism genes examined MTHFR, MTR and MTHFD1 together rather than separately, reporting associations across the group.[10]
Four enzymes, four different jobs
Each of these sits at a different point in the same cycle, and each depends on a different nutrient to function.
| Enzyme | Role in the cycle | Key nutrient |
|---|---|---|
| MTHFR | Makes the active folate form that donates the methyl group | Riboflavin (B2) |
| MTHFD1 | Three reactions directing folate towards DNA synthesis | Folate |
| MTR | Converts homocysteine back into methionine | Vitamin B12 |
| MTRR | Regenerates the B12 cofactor that MTR depends on | Vitamin B12, riboflavin |
A slow step anywhere along this sequence can raise homocysteine. That is why the marker is informative about the pathway as a whole, and why it cannot be attributed to one gene without looking at nutrient status as well.
Why a gene result can't tell you your current status
Genotype is fixed. Whatever variants someone carries, they carried at birth and will carry at eighty. Nutrient status is the opposite, moving with intake, absorption, gut health, alcohol, pregnancy, age and several common medications. The cycle's output is the product of both, and only one can change.[13]
Hence the professional guidance. The American College of Medical Genetics recommended against MTHFR polymorphism testing in a routine workup, because the result rarely alters management.[11] An Australian review reached a similar position, noting how often it is ordered where it cannot change a decision, and how often it is over-interpreted.[12]
For anyone who has already had the test, the consequence is practical. A report showing one or two copies of C677T is not a diagnosis, and does not establish that the folate cycle is currently underperforming. It describes one enzyme's baseline efficiency.
Australia has added folic acid to bread-making flour since 2009, lifting population folate intake substantially.[19] Low folate is therefore less common here than the volume of online concern about MTHFR would suggest, which makes measuring status rather than assuming it more useful, not less.
What we measure instead
Homocysteine is the first and most informative number. It integrates the whole remethylation pathway, rises when folate or B12 is insufficient, and responds to treatment, so it can be repeated later to confirm that something actually worked.[13][16]
Vitamin B12 needs more care than a single serum result, most of which is bound to a protein that cannot deliver it to cells. Active B12, or holotranscobalamin, measures the available fraction, and methylmalonic acid rises when B12 is functionally short at tissue level. Reviews recommend combining markers, since a result inside the reference range does not rule out a functional deficiency.[14][15] We covered that in the B12 deficiency that hides behind a normal result.
Folate is read alongside it. High folate intake with low B12 is the pattern worth identifying, because folate can partly correct the blood picture of B12 deficiency while the neurological effects continue.[17][18] That finding has nothing to do with genotype.
A second remethylation route through betaine and choline runs independently of folate, and intake of both has been associated with homocysteine concentrations.[20] The pathway has more than one entrance.
How we approach it in clinic
When someone arrives with an MTHFR result and a list of symptoms, the result goes to the bottom of the pile rather than the top. What matters first is whether the cycle is running well now, which homocysteine, active B12 and folate answer, read against diet, medications, gut function and history.
If those markers are unremarkable, a C677T result alone does not usually warrant intervention. If they are not, the work is finding out why, which may have nothing to do with the genes in this article. Low intake, poor absorption, coeliac disease, long-term acid suppression or metformin, alcohol and thyroid dysfunction all appear regularly.[13]
Large trials of homocysteine-lowering with B vitamins produced disappointing cardiovascular results, which is worth stating plainly.[16] Lowering a number is not the same as improving an outcome. We measure it diagnostically: it shows where the pathway is strained and whether a correction held. Supplementation follows testing, and depends on the individual picture rather than a genotype.
For the broader clinical context, see our pages on MTHFR and methylation, brain fog and mood and chronic fatigue and burnout, or read more about functional testing.
Key Insights
Frequently Asked Questions
Should I get tested for MTHFR?
For most people, no. The American College of Medical Genetics reviewed the evidence and recommended against MTHFR polymorphism testing as part of a routine workup, because the result rarely changes what is done next. An Australian review reached the same conclusion. If you have symptoms that suggest a problem with folate or B12, measuring homocysteine, active B12 and folate answers a more useful question, since those markers describe how the pathway is running now and can be repeated after treatment.
What are MTHFD1, MTR and MTRR?
They are three more enzymes in the same folate cycle. MTHFD1 is a single protein that carries out three reactions, mostly directing folate towards DNA synthesis. MTR, or methionine synthase, performs the step that converts homocysteine back into methionine and requires vitamin B12 to work. MTRR regenerates that B12 cofactor after it oxidises. Common variants in each have been associated with folate handling and homocysteine concentrations, which is why focusing on MTHFR alone gives an incomplete picture of the pathway.
Does having the MTHFR C677T variant mean I need methylfolate?
Not automatically. The variant reduces enzyme efficiency, but whether that produces a measurable problem depends on your folate and B12 status, which vary with diet, absorption, medication and life stage. Many people carrying the variant have entirely normal homocysteine. The sensible sequence is to measure homocysteine, active B12 and folate first, then decide whether anything needs correcting and in what form. Dosage and the choice of supplement are determined by individual assessment and testing, not by a genotype.
What does a high homocysteine level actually mean?
It means the remethylation pathway is not keeping up, though it does not identify which step is responsible. Insufficient folate, B12 or riboflavin can raise it, as can impaired absorption, some medications, thyroid dysfunction, reduced kidney function and heavy alcohol intake. Because it integrates the whole cycle, homocysteine is useful for detecting that something is under strain and for checking whether a correction has held. Interpreting it properly means looking at nutrient status and medical history alongside the number.
Can taking folate hide a vitamin B12 deficiency?
It can mask part of it. Folate can partially correct the enlarged red blood cells that often prompt investigation of B12 deficiency, while the neurological effects of low B12 continue unaddressed. This is the main reason folate and B12 are measured and interpreted together rather than in isolation, and why a folate supplement taken without knowing B12 status is not a neutral decision. Australia has fortified bread-making flour with folic acid since 2009, so background folate intake here is already substantial.
Ready to find answers?
If you have an MTHFR result you were never given much context for, or symptoms that have been attributed to it without testing, the useful next step is measuring how the pathway is actually running.
References
- Froese DS, Fowler B, Baumgartner MR. Vitamin B12, folate, and the methionine remethylation cycle – biochemistry, pathways, and regulation. J Inherit Metab Dis. 2019;42(4):673–685. PMID: 30693532
- Lyon P, Strippoli V, Fang B, Cimmino L. B Vitamins and One-Carbon Metabolism: Implications in Human Health and Disease. Nutrients. 2020;12(9):2867. PMID: 32961717
- Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64(3):169–172. PMID: 9719624
- Wilson CP, Ward M, McNulty H, et al. The MTHFR C677T polymorphism, B-vitamins and blood pressure. Proc Nutr Soc. 2010;69(1):156–165. PMID: 19954568
- Adam MP, Feldman J, Mirzaa GM, et al., eds. Homocystinuria due to Deficiency of N(5,10)-Methylenetetrahydrofolate Reductase Activity. GeneReviews. Seattle: University of Washington. PMID: 40440437
- Rooney M, Bottiglieri T, Wasek-Patterson B, et al. Impact of the MTHFR C677T polymorphism on one-carbon metabolites: Evidence from a randomised trial of riboflavin supplementation. Biochimie. 2020;173:91–99. PMID: 32330571
- Christensen KE, Rohlicek CV, Andelfinger GU, et al. The MTHFD1 p.Arg653Gln variant alters enzyme function and increases risk for congenital heart defects. Hum Mutat. 2009;30(2):212–220. PMID: 18767138
- Ho V, Massey TE, King WD. Effects of methionine synthase and methylenetetrahydrofolate reductase gene polymorphisms on markers of one-carbon metabolism. Genes Nutr. 2013;8(6):571–580. PMID: 24101362
- Gaughan DJ, Kluijtmans LA, Barbaux S, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis. 2001;157(2):451–456. PMID: 11472746
- Pawlik P, Blazewicz A, Sawicki W, et al. Common Variants in One-Carbon Metabolism Genes (MTHFR, MTR, MTHFD1) and Depression in Gynecologic Cancers. Int J Mol Sci. 2023;24(16):12574. PMID: 37628752
- Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013;15(2):153–156. PMID: 23288205
- Long S, Goldblatt J. MTHFR genetic testing: Controversy and clinical implications. Aust Fam Physician. 2016;45(4):237–240. PMID: 27052143
- Han L, Liu Y, Wang C, et al. Determinants of hyperhomocysteinemia in healthy and hypertensive subjects: A population-based study and systematic review. Clin Nutr. 2017;36(5):1215–1223. PMID: 27908565
- Sobczyńska-Malefora A, Delvin E, McCaddon A, et al. Vitamin B12 status in health and disease: a critical review. Diagnosis of deficiency and insufficiency. Crit Rev Clin Lab Sci. 2021;58(6):399–429. PMID: 33881359
- Devalia V, Hamilton MS, Molloy AM. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166(4):496–513. PMID: 24942828
- Ebbing M, Bleie Ø, Ueland PM, et al. Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials. J Intern Med. 2010;268(4):367–382. PMID: 20698927
- Morris MS, Jacques PF, Rosenberg IH, Selhub J. Circulating unmetabolized folic acid and 5-methyltetrahydrofolate in relation to anemia, macrocytosis, and cognitive test performance in American seniors. Am J Clin Nutr. 2010;91(6):1733–1744. PMID: 20357042
- Plumptre L, Masih SP, Ly A, et al. High concentrations of folate and unmetabolized folic acid in a cohort of pregnant Canadian women and umbilical cord blood. Am J Clin Nutr. 2015;102(4):848–857. PMID: 26269367
- Rabovskaja V, Parkinson B, Goodall S. The cost-effectiveness of mandatory folic acid fortification in Australia. J Nutr. 2013;143(1):59–65. PMID: 23223683
- Chiuve SE, Giovannucci EL, Hankinson SE, et al. The association between betaine and choline intakes and the plasma concentrations of homocysteine in women. Am J Clin Nutr. 2007;86(4):1073–1081. PMID: 17921386
